Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend?

Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend?

Incyte stock popped in premarket trading Tuesday after the biotech company said its cream eczema treatment, dubbed ruxolitinib cream, succeeded in the first of two pivotal studies.